Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.

WEBINAR
End-to-end genotoxicity assessment services for rapid development of CRISPR-based therapies

Available on-demand

As CRISPR-based therapies advance rapidly, conducting comprehensive off-target analysis is critical despite short timelines.

This webinar introduces a comprehensive, scalable framework for off-target risk assessment that integrates orthogonal nomination strategies, including cell‑based (UNCOVERseq), in vitro (CHANGE-seq and ONE-seq), and in silico approaches. Designed to support rapid decision-making, this framework helps researchers and developers prioritize and confirm off-target sites using targeted deep sequencing with our rhAmpSeq™ CRISPR Analysis System.

Case study overview:

We'll walk you through how this approach can be applied across a range of gene editing programs, with a case study highlighting its use in a time-sensitive pediatric setting involving a novel base editor for a severe urea cycle disorder with results published in the New England Journal of Medicine.


Fill out the form below to view webinar on-demand

Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.
Click the HTML icon in the toolbar above to edit spacer height.
TO EDIT: Change the class="spacer-3" to any number between 0 (none) and 5 (most) to resize a spacer. Ex. class="spacer-5"
Vertical spacers are responsive and 50% smaller on mobile than on tablet+.

Presenters

Ashley Jacobi
Ashley Jacobi

Director, Applications and Market Development,
Integrated DNA Technologies

Ashley received her Molecular Genetics & Biochemistry degree from Cornell College in 2006 and has spent the last 19 years in several roles within the Research & Product Development teams at IDT. She has conducted research in RNAi and antisense oligo technologies, and more recently focused on studying CRISPR gene editing. Ashley is also a certified practitioner in Customer Insight and leads external scientific collaborations at IDT.

Adam Chernick
Adam Chernick

Sr. Commercial Product Manager,
Integrated DNA Technologies

Dr. Adam Chernick completed his Bachelor of Health Sciences in Biomedical Sciences and his PhD in Veterinary Medical Sciences at the University of Calgary, Canada. He also holds an MBA from Athabasca University, Canada. He has worked at IDT for nearly a decade in commercial roles with increasing focus on gene editing using CRISPR-based tools. Adam has extensive experience in experimental design, troubleshooting, and technical consultations, with a focus on customer success.